Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data
Objective: Ustekinumab is used in moderate-severe plaque psoriasis with inadequate response to anti- tumour necrosis factor α drugs. Recent studies support the need to assess real long-term data. The aim of this study was to evaluate the real long-term effectiveness and safety of ustekinumab...
| الحاوية / القاعدة: | Farmacia Hospitalaria |
|---|---|
| المؤلفون الرئيسيون: | , , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
Elsevier
2020-09-01
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://www.aulamedica.es/fh/pdf/11420.pdf |
